Original articleEfficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
Key words
Abbreviations used
Cited by (0)
This study was sponsored by Anacor Pharmaceuticals which was acquired by Pfizer Inc on June 24, 2016.
Disclosure: Anacor Pharmaceuticals, Inc, supplied grants to the institutions of Drs Tom, Lebwohl, Boguniewicz, Call, Simpson, Stein Gold, Zaenglein, and Hebert to conduct the studies. Drs Paller, Eichenfield, Simpson, and Spellman received consulting fees from Anacor Pharmaceuticals, Inc, and Drs Forsha, Zaenglein, Hebert, and Stein Gold received advisory board honoraria. The institution of Dr Tom received funding from Otsuka Inc and Regeneron Inc to conduct clinical trials. The institution of Dr Simpson received funding from Merck Inc, Sanofi-Regeneron, Chugai, Amgen, Celgene, MedImmune, Roche/Genentech, Dermira, and Tioga to conduct clinical trials. Dr Simpson received consultant fees from Sanofi-Regeneron, Galderma, MedImmune, Roche/Genentech, Pfizer, Valeant Pharmaceuticals, and Celgene. Dr Stein Gold received advisory board and speaker honoraria from Celgene, and her institution received funding from Celgene and Otsuka Inc to conduct clinical trials. Dr Lebwohl received investigator and/or consulting funds from AbGenomics, Amgen, Boehringer Ingelheim, Celgene, Ferndale, Lilly, Janssen Biotech, Kadmon, LEO Pharmaceuticals, MedImmune, Novartis, Pfizer, Sun Pharmaceuticals, and Valeant. Dr Forsha received advisory board honoraria from Cipher Pharmaceuticals and Valeant Pharmaceuticals. The institution of Dr Hebert received funding from Galderma, Celgene, Amgen, and Merz to conduct clinical trials. Drs Blumenthal and Zane and Ms Hughes are employees and/or stockholders of Anacor Pharmaceuticals, Inc. Dr Rees has no conflicts of interest to declare.
Supplementary figures and tables as well as a list of participating study sites and investigators are available at http://www.jaad.org.